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INTRODUCTION 
Now a day‟s The Pharmaceutical scientists and 
academicians emphasize on the development in newer 
drug delivery system which focuses on the drug targeting 
to achieve high therapeutic effects and minimize adverse 
effects
1
.The NDDS includes various carriers such as 
natural and synthetic polymers, polysaccharides, 
monoclonal antibodies and other biodegradable polymers. 
It also enlists multi-component structure like liposome, 
microcapsules, lipoproteins, microparticles, ghost cells and 
cells. 
The cellu lar carrier for drug delivery includes fibroblasts 
and erythrocytes, leukocytes, platelets  and hepatocytes. 
Resealed erythrocytes are one of the most reviewed  
systems for targeted delivery because they have one of the 
most interesting novelties in the development of cell-
carrier drug delivery systems. Erythrocytes cells can be 
loaded with drugs and these can then be released during 
circulat ion or at targeted sites. Among the cells studied are 
erythrocytes as these cells offer many advantages 
including prolonged delivery times and an elevated 
biocompatibility
2
.  
CHARACTERIZATION OF ERYTHROCYTES: 
Erythrocytes (RBCs) have the basic function to transport 
oxygen in the blood. Erythrocytes appear to be circular  
from the top and side view shows that they are actually 
biconcave discs with diameter of 7.8 μm and thickness 
aprx 2.2 μm.  Th is shape increases the surface area-to-
volume rat io of the cell, thus increasing the efficiency of 
diffusion of O2 and CO2 into and out of the cell. 
Erythrocytes also have a flexible plas ma membrane which  
is very useful during drug loading process .
5,6,7
 
 
 
Figure 1: Erythrocytes as a Carrier 
ABSTRACT 
The current Pharmaceutical scenario focuses only on the development of targeted and sustained drug delivery systems to 
achieve required therapeutic concentration with less amount of dose. Among the various carriers used for targeting of the drugs 
to various body tissues, the encapsulated erythrocytes meet several criteria desirable in clinical applications, among the most 
important being biocompatibility as a carrier and its degradation products.  Erythrocytes loaded with drugs and other substances 
have different release rates. Encapsulated erythrocytes permit controlled release of drug and increase specificity of delivery to 
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SUITABILITY OF ERYTHROCYTES AS DRUG 
CARRIER 
Erythrocytes as a Carrier are one of the innovative drug 
delivery systems used for years . These are elastic, 
biconcave shape which enables them to squeeze through 
narrow capillaries and are selectively removed from 
circulat ion by the macrophages in the Reticulo Endothelial 
System (RES), hence be able to used in targeting of drugs 
to RES. The average life span of RBCs is 100-120 days in 
the circulation so can be used for sustained delivery of 
therapeutic agents.
8 
They posses various characterstics like  easy isolation, 
biocompatibility, specific physico-chemical propert ies, 
High drug loading efficiency , Low leaching or leakage of 
drug  and have enough volumes for loading drug. 
Eryhrocytes modify the pharmacokinetic and 
pharmacodynamic parameter of drug.It also minimizes  the 
toxic effect of drug due to fluctuation in concentration to 
protect the organism. The breakdown products are 
recycled; hemoglobin is breakdown into globin and heme. 
Globin  degraded to amino acids for amino acid pools in  
the body, while iron reused in hemoglobin synthesis; 
therefore, they are well suited to be used as drug carriers.
9 
ADVANTAGES OF ENCAPS ULATED 
ERYTHROCYTES  
Erythrocytes can be used as carriers in two ways; one is 
that Targeting particular tissue or organ using only the 
erythrocyte membrane and other is for continuous or 
sustained release of drugs which provide prolonged drug 
action. They remain in the circu lation for prolonged 
periods of time (apprx. 120 days) and release the entrapped 
drug at a slow and steady rate
3,4
. 
The entrapment of drug does not require the chemical 
modification of drugs. They are non immunogenic in  
action and can be targeted to diseased tissue/organ. They 
facilitate incorporation of protein and nucleic acid  in  
eukaryotic cells by cell infusion with RBC. In addition, 
they can be used as substitute carriers instead of 
liposomes, Ethosomes, Niosomes, nanoparticles, 
micropart icles or microspheres that have been used for the 
controlled Drug delivery. 
DISADVANTAGES 
10,11,12,13
  
 Limited potential as carrier to nonphagocytic target 
tissue. 
 Given that they are carriers of biological origin, 
encapsulated erythrocytes may present greater 
variability and lesser standardisation in their 
preparation, compared to other carrier systems. 
 Possibility of clumping of cells  and Dose dumping 
may also be there. 
 The leakage of certain encapsulated substances may 
be there from the loaded erythrocytes. 
 Several molecules may alter the physiology of the 
erythrocyte. 
 Liable to biological contamination due to the origin 
from the blood, the equipment used and the loading 
environment. Rigorous controls are required  
accordingly for the collection and handling of the 
erythrocytes. 
 The storage of the loaded erythrocytes is a problem 
involving carrier erythrocytes for their possible use in 
therapeutics. Tests have been performed on their 
conditioning in suspension in isotonic buffers 
containing all essential nutrients, as well as in low 
temperatures, with the addition of nucleosides or 
chelators, lyophilisation, freezing with glycero l or gel 
immobilization. 
SOURCE AND ISOLATION OF ERYTHROCYTES  
Different mammalians like humen, monkies, horses, 
sheeps, goats, rabbits etc., are used for the collection of 
erythrocytes
14
. Usually to isolate erythrocytes, blood is 
collected into heparinised tubes by venipuncture. EDTA or 
heparin can be used as an anticoagulant. Whole blood from 
horse, sheep, goat, dog and rabbit is easily collected 
through venipuncture. Fresh whole blood is defined as any 
blood collected and immediately chilled to 4 0C and stored 
for not more than 2 days. Red blood cells are harvested 
and washed by centrifugation. After recovering the blood 
from vain puncture and mix with heparin, it is centrifuged 
at 2000 rpm for 5 min at 4 ±1 
0
C. This helps in separation 
of plasma and Buffy coat. Erythrocytes so obtained are 
washed three times with buffer solution. These 
erythrocytes are diluted with phosphate buffer and often 
stored in acid-citrate-dextrose buffer at 4 0C up to 48 hrs 
prior to use. 
Table 1: Source and Isolation of erythrocytes
 14-17
 
Species  Washing buffer  Centrifugal force(g)  
Rabbit  10mmol KH2P04 /NaHPO4  500-1000  
Dog  15mmol KH2P04 /NaHPO4  500-1000  
Human  154mmolNaCl  <500  
Mouse  10mmol KH2P04 /NaHPO4  100-500  
Cow  10-15mmol KH2P04 /NaHPO4  1000  
Horse  2 mmolMgCl2, 10 g lucose  1000  
Sheep  10 mmol KH2P04 /NaHPO4  500-1000  
Pig  10 mmolKH2P04 /NaHPO4  500-1000  
 
IDEAL PROPERTIES OF DRUGS
10, 11 
 The Drug should be polar and hydrophilic. 
 The drug should resist degradation within  
erythrocytes. 
 It should not have any physical or chemical interaction 
because drug molecules  (non polar and hydrophobic 
drugs) which interact with the membrane and cause 
deleterious effects on membrane structure so these are 
not considered to be appropriate for encapsulation in 
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erythrocyte.  
 It should have well defined pharmacokinetic and 
pharmacodynamic properties.  
 Variety of bio logically active substance i.e. mol wt 
ranges from 5000-60,000 Dalton can be entrapped in 
erythrocytes.  
DRUG LOADING METHODS  
Various methods can be used to load drugs or other 
bioactive compounds in erythrocytes, including physical 
(electrical pulse method) osmosis -based systems, and 
chemical methods (chemical perturbation of the 
erythrocytes membrane).                       
1. Hypo-os motic lysis method for drug loading  
Various methods for Hypo-osmotic lysis are discussed in 
table below: 
Table 2: Hypo-osmotic lysis method for drug loading in erythrocyte
26-27
 
 
2. Chemical perturbation of the membrane28-29 
According to this method the membrane permeability of 
erythrocytes increase when the cells are exposed to certain 
chemicals. The permeability of erythrocytic membrane 
increases upon exposure to polyene antibiotic such as 
amphotericin B. The antineoplastic drug daunomycin was 
introduced successfully in human and mouse erythrocytes. 
This method has been established by Lin et al for same 
purpose using halothane.
30
 However; this method is not 
very popular because it induces irreversible destructive 
changes in the cell membrane. 
3. Electro-insertion or electroencapsulation31-35 
This method is based on the observation that electrical 
shock brings about irreversible changes in an erythrocyte 
membrane
31.
  The erythrocyte membrane is opened by a 
dielectric breakdown. Subsequently, the pores can be 
resealed by incubation at 37 
0
C in an isotonic medium.  
The procedure involves suspending erythrocytes in an 
isotonic buffer in an electrical discharge chamber. A 
capacitor in an external circuit is charged to a definite 
voltage and then discharged 
Within a definite time interval through cell suspension to 
produce a square-wave potential . The optimum intensity 
of an electric field is between 1–10 kW/cm and optimal 
discharge time is between 20–160 µs. An inverse 
relationship exists between the electric-field intensity and 
the discharge time. The compound to be entrapped is 
added to the medium in which the cells are suspended 
from the commencement of the experiment. The 
characteristic pore diameter created in the membrane 
depends upon the intensity of electric field, the discharge 
time, and the ionic strength of suspending medium. The 
colloidal macromolecu les contents of the cell may lead to 
cell lysis because of the increase in osmotic pressure. This 
process can be prevented by adding large molecules (e.g., 
tetrasaccharide stachyose and bovine serum albumin) and 
ribonucleose
64
. One advantage of this method is a more 
uniform d istribution of loaded cells in  comparison with 
osmotic methods. The main drawbacks are the need for 
special instrumentation and the sophistication of the 
process. Entrapment efficiency of this method is close to 
35%. Various compounds such as sucrose
36
, urease
39
, 
methotrexate
47
, isoniazid
43
, human g lycophorin
44
, DNA 
fragments, and latex part icles of diameter 0.2 µm can be 
entrapped within erythrocytes
33
. 
4. Entrapment by endocytosis46-48 
In 1975 Schrier et al reported this method by Endocytosis 
involves the additionof one volume of washed packed 
erythrocytes to nine volumes of buffer containing 2.5 mM 
ATP, 2.5 mM MgCl2, and 1mM CaCl2, followed by 
incubation for 2 min at room temperature. The pores 
created by this method are resealed by using 154 mM of 
NaCl and incubation at 37 
0
C for 2 min . The entrapment of 
material occurs by endocytosis. The vesicle membrane 
separates endocytosed material from cytoplasm thus 
protecting it from the erythrocytes and vice-versa. The 
various candidates for example primaquine and related 8–
amino–quinolines, vinblastine, chlorpromazine and related 
Method  Procedure     %           
Loading 
Advantages Disadvantages 
Dilution 
method 
Based upon hypotonic lysis of cells in a solution 
containing the 1-8% Fastest and simplest, Entrapment  
capacity low. Drug/enzyme to be entrapped followed  
by restoration of tonicity especially for low to reseal 
them and also ability of erythrocytes to undergo 
molecular weight drug. Reversible  swelling in a 
hypotonic solution. 
  
 
  1-8 % 
Fastest and 
simplest, especially  
for low molecu lar 
weight drug. 
Entrapment 
capacity low 
Dialysis It can be carrying out lysis and resealing within a 
dialysis tube using hypotonic and isotonic solution 
   
30-40 % 
Better in vivo 
survival.  
Time 
consuming  
Preswell 
dilution 
The technique is based upon initial controlled swelling  
of erythrocytes without lysis by placing them in  
slightly followed by centrifugation at low „g‟ to take 
them up to and good survival in point of lysis. Finally, 
the addition of small volume of drug solution to vivo, 
attain drug loaded resealed erythrocytes. 
   
 
 
20-70 % 
Good retention of 
cytoplasm 
constituents and 
good survival in-
vivo. 
 
Isotonic 
osmotic 
lysis
23
 
Resealed erythrocytes were prepared under isotonic 
conditions. Haemolysis in isotonic solutions can be 
achieved both by chemical agent and physical methods. 
20-70 % Better in vivo 
Surveillance 
Consuming. 
Impermeable 
only to large 
molecules, 
process is time 
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phenothiazines, hydrocortisone, propranolol, tetracaine, 
and vitamin are entrapped by this method
57
. 
5. Lipid Fusion Method 
The lipid vesicles containing a drug can be directly fuse to 
human erythrocytes, which lead to an exchange with a 
lip id entrapped drug. The methods are useful for 
entrapping inositol monophasphte to improve the oxygen 
carrying capacity of cells and entrapment efficiency of this 
method is very low (~1%). 
49 
Use of Red Cell Loader 
50
  
A method for entrapment of non diffusible drugs into 
erythrocytes with equipment called a “red cell loader”  
.With as little  as 50 mL of a blood sample, different 
biologically active compounds were entrapped into 
erythrocytes within a period of 2 hrs. at room temperature 
under blood banking conditions. The process is based on 
two sequential hypotonic dilutions of washed erythrocytes 
followed by concentration with a hemofilter and an 
isotonic resealing of the cells. There was 30% drug loading 
with 35–50% cell recovery. The processed erythrocytes 
had normal survival in vivo. The same cells could be used 
for targeting by improving their recognition by tissue 
macrophages.  
CHARACTERIZATIONS OF ENCAPS ULATED 
ERTYTHROCYTE 
Various characterization parameters are given in table 
below: 
Table 3: Characterization parameters and their determination methods for encapsulated Erythrocytes
36-45
 
1. Physical parameter  
PARAMETER  METHOD /INSTRUMENT US ED  
Shape and surface morphology  Transmission electron microscopy, scanning electron microscopy,  
phase contrast microscopy, optical microscopy  
Vesicle size and size distribution  Transmission electron microscopy, optical microscopy  
Drug release  Diffusion cell, d ialysis  
Drug content  Deproteinization of cell membrane fo llowed by assay of resealed drug, radio-
labelling  
Surface electrical potential  Zeta potential measurement  
Surface Ph  pH-sensitive probes  
Deformability  Capillary method  
 
II. Cellular characterization 
% Hb content  Deproteinization of cell membrane followed by hemoglobin assay  
Cell volume  Laser light scattering  
% Cell recovery  Neubaur‟s chamber, hematological analyzer  
Osmotic frag ility  Stepwise incubation with isotonic to hypotonic saline solutions and determination  
of drug and hemoglobin assay  
Osmotic shock  Dilution with distilled water and estimation of drug and hemoglob in  
Turbulent shock  Passage of cell suspension through 30-gauge hypodermic needle at 10 ml/min flow rate 
and estimat ion of residual drug and hemoglobin, v igorous shaking followed by  
hemoglobin estimation  
Erythrocyte sedimentation rate  ESR methods  
 
III. Biological Characterization 
Sterility  Sterility test  
Pyrogenicity  Rabbit method, LAL test  
Animal toxicity  Toxicity tests  
 
IV. S afety Considerations 
STEPS TO BE CONS IDERED  SAFETY ISS UE  
Different blood types  Blood clotting  
Possible risk of contamination  HIV,HBV etc.  
Changing on physical and possible of clotting  Rigidity of membrane modification on erythrocytes membranes 
biochemical characteristics proteins lead to lysis. Extensive 
biotynilated leads to rapid elimination and kidney problems  
Changing in pharmacokinetic and 
pharmacodynamic behaviors of loaded drug  
Increase the production of unfavorable metabolites  
 
IN-VITRO S TORAGE
32, 34 
The most common storage media include Hank‟s balanced 
salt solution and acid–citrate-dextrose at 4 0C. Cells remain  
viable in terms of their physiologic and carrier  
characteristics for at least 2 weeks at this temperature. 
ROUTE OF ADMINIS TRATION 
60,61 
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Encapsulated erythrocytes are commonly administered by 
IV Route
60
. Intraperitoneal and subcutaneous routes  are 
other means of administration for targeting cells into 
peritoneal macrophages and for sustaining drug release 
respectively. 
MECHANIS M OF RELEAS E OF LOADED DRUGS  
62,63 
There are mainly three ways for a drug release from the 
erythrocyte carriers  
 Phagocytosis: By the process of phagocytosis 
normally erythrocyte cells removed from the blood 
circulat ion. The degree of cross linking determines 
whether liver o r spleen will preferentially remove the 
cells.  
 Diffusion through the membrane of the cells: 
Diffusion through the membrane depends on the drug 
molecule penetrate through a lipid bilayer i.e. 
bioactive compound have lipid solubility.  
 Using a s pecific trans port system: Most of the drug 
molecules enter cells by a specific membrane protein 
system because the carriers are proteins with many 
properties analogous to that of enzymes.  
APPLICATIONS OF ENCAPS ULATED 
ERYTHROCYTES
58,59 
Encapsulated erythrocytes have been used as targeted Drug 
delivery systems for a variety of applications in human and 
veterinary medicine. In vivo application of the drugs 
loaded erythrocytes are used in two ways as for prolonged 
drug released and for drug targeting to RES or non RES.  
The applications of encapsulated erythrocytes are as 
follows: 
[I] In vitro  
The most frequent in vitro application of RBC is that of 
micro -in jection. A protein or nucleic acid was injected into 
eukaryotic cells by fusion process. Similarly, when 
antibody molecules are introduced using erythrocytic 
carrier system, they immediately diffuse throughout the 
cytoplasm. Antibody RBC auto-in jected into living cells 
has been used to confirm the site of action of fragment of 
diphtheria toxin. Antibodies introduced using RBC 
mediated microinject ion is recorded not to enter the 
nucleus, thus limit ing the studies to the cytoplasmic level. 
Encapsulated erythrocytes have been used to facilitate the 
uptake of enzymes by phagolysosomes  for In vitro 
phagocytosis. Enzymes content within carrier RBC could  
be visualized with the help of cytochemical technique. The 
biochemical defects such as the glucose- 6-phosphate 
dehydrogenase (G6PD) deficiency can be useful tool for 
discerning the mechanism that eventually causes these 
effects. Other in vitro tests include utilizat ion of 
erythrocytes carrier to introduce ribosome inactivating 
proteins into cells by fusion technique.
51 
[II] In vivo 
A. Targeting of bioactive agents to RES  
After drug release, remnants of erythrocytes are rapidly  
cleared from circulat ion by phagocytosis. Targeting of the 
drug minimizes its side effects and the dose to be 
administered as well as drug utilization. Modifications of 
erythrocytes membranes by treating them with antibodies, 
gluteraldehyde, sialic acid, ascorbate, ferrous ion, biotin  
and sulfhydryl containing substances accelerate their 
targeting to the liver as well as spleen
18
.  
B. Targeting to sites other than RES-rich Organs 
 Encapsulated Erythrocytes have the ability to deliver a 
drug or enzyme/proteins to the macrophage-rich organs 
and these have been used to target non RES organs. 
Table 4: Encapsulated erythrocytes used in other than RES organ targeting
21-25 
Approaches  Type of Drugs  Application 
Ultrasound Mediated Delivery of 
 Encapsulated Erythrocytes  
Erythrocytes colloidal particles and 
RBC  
Delivery to tissue through micro vessel ruptures created 
by targeted micro bubble destruction with ultrasound.  
Photosensitized Erythrocytes  Methotrexate and photosensitized by 
subsequent exposure to a 
haematoporphyrin derivative  
Useful in the treatment of tumors of body located at site 
other than RES predominant organs or as a phototriggered 
carrier/delivery system for methotrexate in tumor therapy.  
Magnet-responsive Erythrocyte 
Ghosts  
encapsulation of small paramagnetic 
particles into erythrocytes  
Localization to a particular location under the influence of 
external magnetic field.  
Antibody Anchored Erythrocytes 
(Immunoerythrocytes):  
Antibody coating of resealed drug 
carrier  
Drug targeting to the RES.  
 
C. Carrier erythrocytes as slow drug release system 
Sustained release dosage forms are designed to produce a 
prolonged therapeutic effect by continuous drug release 
over an extended period of time after administration of 
single dose.
26                     
Carrier erythrocytes have long life span in the circulation, 
so that they can be used as circulating depots for 
antitumor, antiparasitics, antibiotics as well as 
cardiovascular drugs. This happened only when the drug 
and the selected method for the drug loading don‟t change 
the morphological and physiological parameters of 
erythrocytes. Encapculated erythrocytes serve as an ideal 
carrier fo r antineoplastic agents, antimicrobial drugs, 
vitamins and steroids.
10 
D. Erythrocytes as Carriers for Drugs , Enzymes , 
Proteins, Macromolecules and as a circulating 
bioreactors 
Several drugs like Actinomycin-D, 
Methotrexate,Daunomycin,Etoposide Gentamycin, 
Primaquine and few enzymes L-Asparaginase, 
Aminolevulinate dehydratase have been encapsulated in 
Erythrocytes. Other than these, proteins like Insulin,  
micotoxin and recombinant human erythropoietin 
(rHuEpo) have been encapsulated. Various application of 
encapsulated are given in table below: 
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Table 5: Various application of resealed erythrocytes
19, 20 
Application  Drug/Enzyme/Macromolecule  
Enzyme deficiency rep lacement therapy  β -galactosidase,β-fructofuronodase, urease, glucose 6-phosphatedehydrogenase  
Thrombolytic activity  Brinase, aspirin, heparin  
Iron overload  Desferroxamine  
Chemotherapy  Rubomycin, methotrexate, daunomycin, cytosine  
Immunotherapy  Human recombinant interleukin-2  
Circulat ing bioreactor  Arginase, uriease, luciferase  
 
NOVEL APPROACHES  
Erythrosomes  are specially designed vesicular systems 
that are chemically cross-linked to human erythrocytes, 
support upon which a lipid bilayer is coated. This is 
achieved by modifying a reverse-phase evaporation 
technique. These vesicles have been proposed as useful 
encapsulation systems for macromolecular drugs.
52-54
 
Nanoerythrosomes are prepared by extrusion of 
erythrocyte ghosts to produce small vesicles with an 
average diameter of 100 nm. Daunorubicin was covalently 
conjugated to nanoerythrosomes using gluteraldehyde 
spacer. This complex was more active than free 
daunorubicin alone, both in vit ro and in vivo.
55, 56 
CONCLUSION 
This review focuses on the suitability of erythrocytes as 
biological carriers for therapeutic agents, such as drugs, enzymes 
and peptides. Encapsulated erythrocytes are effective and safe for 
targeted and sustained Drug delivery systems with less or no 
toxicity. Through unexpected twist and turns, encapsulation of 
erythrocytes became a game changing technology for 
pharmaceutical sciences. However, the concept needs further 
optimization to become a routine drug delivery system. 
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